Niche market Delee focuses on circulating tumor cell isolation and imaging for early cancer detection and treatment monitoring, presenting a targeted opportunity to engage oncology clinics, cancer centers, and personalized medicine programs seeking advanced CTC workflows.

Early-stage revenue With annual revenue under one million and a small team, Delee may be receptive to affordable, modular solutions, service contracts, and pilot programs that minimize upfront costs while proving value.

Clinical workflow fit The CytoCatch platform automates CTC isolation and staining, followed by imaging analysis, suggesting sales emphasis on seamless integration with existing lab processes, sample throughput considerations, and user-friendly interface comparisons.

Tech stack leverage Utilize cloud and web technology familiar to their stack (Google Cloud, Cloudflare, modern JS tools) to propose scalable data management, secure storage, and analytics integrations that align with their IT readiness.

Growth comparables Given parallels to established biotech players in life sciences instrumentation, highlight potential partnerships, distribution, or co-development opportunities with large multipliers in the field while tailoring messaging to mid-size teams accustomed to rapid proof-of-concept cycles.